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The role of the HLA system in Hodgkin lymphoma (HL) susceptibility has been known 
for many years. Large genome-wide association studies (GWAS) also identified genetic variants 
outside of the HLA region, including 2p16.1 (near REL, rs1432295), 8q24.21 (near MYC/PVT1, 
rs2608053 and rs2019960), 10p14 (near GATA3, rs501764 and rs485411) and 19p13.3 (intron 2 
of TCF3, rs1860661) (Enciso-Mora et al 2010; Cozen et al, 2014). REL, which encodes c-rel, a 
member of the NFkB pathway is activated in classical HL (cHL) and GATA3 is aberrantly 
expressed in cHL. PVT1, which is downstream of the MYC locus, encodes five non-coding 
microRNAs (miR-1204, 1205, 1206, 1207, 1208), with suspected oncogenic properties (Barsotti 
et al, 2012). TCF3, a crucial gene for lymphoid progenitor commitment in B-cell and T-cell 
lineages, is disturbed in cHL (Renne et al, 2006). We investigated whether single nucleotide 
polymorphisms (SNPs) at 6p21 (HLA-DRA), 2p16 (REL), 8q24 (MYC/PVT1), 10p14 (GATA3) 
and 19p13.3 (TCF3) associated with HL susceptibility were also associated with outcome in two 
independent prospective cohorts.     
 The first cohort consisted of 342 cHL patients enrolled in a prospective biologic study of 
the Lymphoma Study Association (LYSA) and the second cohort consisted of 239 cHL patients 
prospectively enrolled in the University of Iowa/Mayo Clinic Specialized Program of Research 
Excellence (SPORE) Molecular Epidemiology Resource (Casasnovas et al, 2007; Thompson et 
al, 2011). The clinical characteristics of these patients are presented in Table S1. Patients were 
mainly treated with ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) in LYSA (85%) 
and SPORE (90%). After a median follow-up of 5 years (range 0.04-9.75), the 5-year 
progression-free survival (PFS) and overall survival (OS) were 83% and 92% for the LYSA 
patients, respectively. After a median follow-up of 7.8 years (range 0.45-11.03), the PFS and OS 
for the SPORE cohort were 76% and 86%, respectively.  
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A peripheral blood sample for DNA analysis was collected from all patients. Details of 
DNA extraction and genotyping are presented in the Supporting Information. The seven SNPs 
genotyped from 2p16 (REL, rs1432295), 6p21 (HLA-DRA, rs6903608), 8q24 (MYC/PVT1, 
rs2608053 and rs2019960), 10p14 (GATA3, rs501764 and rs485411) and 19p13.3 (TCF3, 
rs1860661) had a similar minor allele frequency (MAF) between the two study cohorts (Table 
S2) and frequencies were consistent with prior studies (Enciso-Mora et al, 2010; Cozen et al, 
2014). No significant correlation between the seven SNPs and the international prognostic score 
(IPS) was showed (Table S3 and S4). 
 Correlation between the seven SNPs and outcome is presented in Table I. In LYSA, 
GATA3 (rs501767) was associated with PFS (HR=1.86; 95%CI, 1.11-3.12; P=0.02). There were 
suggestive associations for MYC/PVT1 (rs2608053) (HR=1.76; 95%CI, 0.95-3.26; P=0.07) and 
REL (rs1432295) (HR=0.63; 95%CI 0.37-1.06; P=0.08). In SPORE, only MYC/PVT1 
(rs2608053) was associated with PFS (HR=2.22; 95%CI, 1.09-4.54; P=0.03). In a meta-analysis 
of the two studies, MYC/PVT1 (rs2608053) was significantly associated with PFS (HR=1.94; 
95%CI, 1.22-3.10; P=0.01), and adjustment for IPS did not alter the results (HR=1.83; 95%CI, 
1.13-2.96; P=0.03). In SPORE, MYC/PVT1 (rs2608053) was also associated with OS (HR=2.52; 
95%CI, 1.06-6.00; P=0.04), while in LYSA the HR was attenuated (HR=1.38; 95%CI, 0.65-
2.96; P=0.40). The number of deaths was lower in the LYSA cohort, limiting the power to detect 
a statistically significant difference for OS. In a meta-analysis of OS in the two studies, the 
pooled estimate for MYC/PVT1 (rs2608053) was statistically significant in univariate analysis 
(HR=1.80; 95%CI, 1.01-3.18; P=0.04), but not after IPS adjustment (HR=1.60; 95%CI, 0.89-
2.85; P=0.11). Survival curves comparing patients with MYC/PVT1 (rs2608053) GG vs AG+AA 
genotypes are presented in Fig 1. The second SNP in the MYC/PVT1 locus (rs2019960) was 
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associated with OS in only the SPORE cohort (HR=0.49; 95%CI, 0.26-0.93; P=0.03). In an 
exploratory analysis, associations of MYC/PVT1 (rs2608053) with PFS were stronger for older 
age (≥45 years), male sex, nodular sclerosis subtype, and stage I-II disease (Table S5).  
We conducted exploratory analyses assessing these SNPs with PFS stratified by EBV 
status (Table S6). The only significant association was observed for the HLA-DRA SNP 
(rs6903608) with PFS in EBV- cHL from the SPORE cohort (HR=0.35; 95%CI, 0.13-0.94; 
P=0.04); a much weaker association was observed in the LYSA cohort (HR=0.67; 95%CI, 0.30-
1.51) (P=0.33). These suggestive results could parallel the findings of risk studies in which the 
HLA class II SNP rs6903608 was mainly linked to EBV- cHL susceptibility (Enciso-Mora et al, 
2010; Urayama et al, 2012). 
In this study, we observed that one risk SNP (rs2608053) for cHL at 8q24 near the 
MYC/PVT1 locus was associated with patient outcome. The function of miR-1204, 1205, 1206, 
1207 and 1208 in cHL pathogenesis is currently unknown. The prognostic association of 
MYC/PVT1 rs2608053, a non-coding SNP, could be related to miRs or MYC deregulation. We 
found 14 SNPs in linkage disequilibrium (LD) with rs2608053 at r2>0.50 (Table S7). None of 
these SNPs was in strong LD with SNPs within the miR genes in or near MYC. One of these 
SNPs, rs2720660 (r2=0.52), was localized at -156 bp 5’ of pre-miR-1207 in an active regulatory 
region (Fig S1). A previous study showed that PVT1 transcripts including miR-1207 are induced 
by daunorubicin in a P53 dependent manner leading to cell cycle alterations and apoptosis 
(Barsotti et al, 2012). In a gastric cancer model, miR-1207-5p reduced in vitro proliferation by 
targeting the telomerase reverse transcriptase, in favour of an anti-oncogenic function (Chen et 
al, 2014). Recently, miR-217 overexpression was found to promote B-cell lymphoma by the 
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suppression of DNA damage response and the stabilization of BCL6 that induces germinal center 
reaction (de Yebenes et al, 2014). Our bioinformatics research (Fig S2) showed that miR-1207-
5p could also negatively regulate BCL6 via the heparin binding epidermal growth factor gene 
(HBEGF) and that HBEGF is expressed in lymph nodes (Fig S3). One model in CFHR5 
nephropathy confirmed that miR-1207-5p is effectively a target of HBEGF (Papagregoriou et al, 
2012).  
In conclusion, the cHL susceptibility locus rs2608053 at 8q24 was associated with PFS in 
two independent cohorts of cHL. Whether some polymorphisms at 8q24 locus could influence 
the functionality of translated miRs of this region and consequently cHL development and tumor 
sensitivity to cHL treatment need additional studies. 
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Fig 1.  Outcome of classical Hodgkin lymphoma patients according to MYC/PVT1 (rs2608053) 
genotype. Progression-free survival in LYSA (1A) and in the SPORE cohorts (1B). Overall 
survival in LYSA (1C) and in the SPORE (1D). Progression-free survival was measured from 
the date of initiation of therapy (LYSA) or the date of diagnosis (SPORE) to the date of first 
relapse, progression, retreatment, or death (any cause). Overall survival was evaluated from the 
date of initiation of therapy (LYSA) or the date of diagnosis (SPORE) to the date of death from 
any cause. Survival was estimated by the Kaplan-Meier product limit method and compared 
using the log-rank test. 
1A 
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Table I. Univariate associations of SNPs (dominant model) with progression-free and overall survival in classical Hodgkin lymphoma 
 
 Progression-Free Survival  Overall Survival 
 LYSA  SPORE  Combined analysis  LYSA  SPORE  Combined analysis 
Gene and SNP HR (95%CI) P   HR (95%CI) P  HR (95%CI) P  HR (95%CI) P  HR (95%CI) P  HR (95%CI) P 
REL, rs1432295 0.63 (0.37-1.06) 0.08   1.01 (0.57-1.76) 0.99  0.78 (0.53-1.15) 0.21  0.52 (0.27-1.03) 0.06  1.36 (0.68-2.71) 0.38  0.84 (0.52-1.36) 0.47 
HLA-DRA, rs6903608 0.95 (0.54-1.68) 0.87   0.70 (0.41-1.18) 0.18  0.81 (0.55-1.18) 0.27  0.83 (0.40-1.70) 0.61  0.80 (0.43-1.48) 0.48  0.81 (0.51-1.30) 0.38 
MYC/PVT1, rs2608053 1.76 (0.95-3.26) 0.07   2.22 (1.09-4.54) 0.03  1.94 (1.22-3.10) 0.01  1.38 (0.65-2.96) 0.40  2.52 (1.06-6.00) 0.04  1.80 (1.01-3.18) 0.04 
MYC/PVT1, rs2019960 1.16 (0.69-1.94) 0.57  0.71 (0.42-1.21) 0.21  0.91 (0.63-1.32) 0.64  0.93 (0.47-1.83) 0.84  0.49 (0.26-0.93) 0.03  0.67 (0.42-1.06) 0.09 
GATA3, rs501764 1.86 (1.11-3.12) 0.02  0.71 (0.41-1.23) 0.23  1.18 (0.81-1.72) 0.38  1.06 (0.54-2.10) 0.86  0.75 (0.40-1.41) 0.37  0.88 (0.55-1.40) 0.59 
GATA3, rs485411 1.43 (0.85-2.39) 0.18  1.10 (0.65-1.86) 0.72  1.25 (0.87-1.81) 0.23  0.77 (0.39-1.52) 0.45  1.05 (0.57-1.92) 0.88  0.91 (0.58-1.44) 0.70 
TCF3, rs1860661 1.10 (0.61-1.98) 0.74  1.42 (0.78-2.59) 0.25  1.25 (0.82-1.90) 0.30  1.45 (0.64-3.28) 0.37  1.40 (0.71-2.73) 0.33  1.42 (0.84-2.38) 0.19 
Abbreviations: HR, hazard ratio; CI, confidence interval; SNP, single nucleotide polymorphism. 
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Supporting information 
Data S1: Genotyping conditions 
A peripheral blood sample for DNA was collected from all patients in the two studies. These 
studies were approved by the ethics committees from Dijon and Lyon University Hospitals 
(LYSA) and Mayo Clinic and the University of Iowa Institutional Review Boards (SPORE). 
All patients provided written consent for participation. DNA for genotyping was extracted using 
standard protocols. In the LYSA, SNPs at 6p21 (HLA-DRA, rs6903608), 8q24 (MYC/PVT1 
rs2608053 and rs2019960), 10p14 (GATA3, rs501764) and rs485411) were analyzed using a 
complete commercially available assay (Applied Biosystems, Foster City, California, USA) 
that contains primers, probes and TaqMan Genotyping Master Mix. Real-time PCR analysis 
was performed on an ABI Prism 7000 Sequence Detection System (Applied Biosystems). The 
REL polymorphism was genotyped by using a PCR-based restriction fragment length 
polymorphism (PCR-RFLP). The amplified fragments of 401 bp were obtained with the use of 
upstream (5’-CTTTACACCTAAATTGTTGTCTTGTG) and downstream (5’-
AGTGCTGGGACTACAGGTATGA) primers. PCR amplification was performed with a first 
step at 94°C for 10 minutes, followed by 35 cycles of 45 s at 95°C, 45 s at 60°C, 1 minute at 
72°C, followed by a final extension step at 72°C for 10 minutes, in a final volume of 50 µL. 
The PCR-amplified products (10 µL) were digested 1 hour at 37°C with 1 unit of Alw26I 
(Fermentas, ThermoScientific). The digested PCR-products were separated by electrophoresis 
on agarose gel. Ten percent of the LYSA samples were duplicates, with 100% concordance of 
genotyping results.  
In the SPORE, all but one of the candidate SNPs (TCF3 at 19p13.3) were genotyped as part of 
a larger project using a custom Illumina Infinium array (Illumina, San Diego, CA) 
(Charbonneau et al, 2013). Standard genotyping quality control procedures were performed and 
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included duplicate genotyping, dropping samples or SNPs with call rates<95%, and testing for 
Hardy-Weinberg equilibrium (HWE). We found >99.9% genotyping concordance among the 
3502 samples with duplicates.  
The genotyping of TCF3 SNP (rs1860661) of the LYSA and the SPORE cohorts was performed 
in the context of a GWAS meta-analysis (Cozen et al, 2014) for HL susceptibility of three 
previous HL GWAS (Cozen et al, 2012; Urayama et al, 2012; Best et al, 2011). Genotyping of 
the LYSA cases was performed by the IARC, and the SPORE series was performed by the 
Molecular Genomics Core of USC (Norris Comprehensive Cancer Center, Los Angeles, CA) 
using TaqMan Pre-Designed SNP Genotyping Assays (Applied Biosystems, Carlsbad, CA). A 
TaqMan Pre-Designed SNP Genotyping Assay Mix (containing probes and primers) was used 
for this SNP (Applied Biosystems assay-on-demand order code C__11969900_10 for 
rs1860661). 
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Data S2. Statistics 
Progression free survival (PFS) was measured from the date of initiation of therapy (LYSA 
series) or the date of diagnosis (SPORE series) to the date of first relapse, progression, 
retreatment, or death (any cause). Overall survival (OS) was measured from the date of 
initiation of therapy (LYSA series) or the date of diagnosis (SPORE series) to the date of death 
(any cause). Patients without an event were censored at date of last follow-up. Kaplan-Meier 
curves and Cox proportional hazards models were used to assess the association of each 
genotype (dominant model) with PFS and OS in both a univariate fashion and after adjusting 
for the international prognostic score (IPS). Analyses were done independently for the two 
cohorts and then to increase power, a meta-analysis approach was used to combine results. 
Analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC, USA) and R 
(http://www.r-project.org/).   
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Table S1. Clinical, biologic characteristics and treatment of classical Hodgkin lymphoma 
patients 
  LYSA  SPORE   
 N=342 (%)  N=239 (%)  P-value 
Median age (range) 32 (15-93)   38 (18-89)  <0.0001 
Age≥45 years    71 (21)    92 (39)  <0.0001 
Male 196 (57)  124 (52)  0.20 
Ethnicity      
   Caucasian -  202 (85)   
   Non-Caucasian -   6 (2)   
   Unknown -a   31 (13)   
ECOG PS      
   0-1 295 (97)   205 (86)  <0.0001 
   2-4   9 (3)    34 (14)   
Histological subtype      
   Nodular sclerosis  288 (84)   161 (67)  <0.0001c 
   Mixed cellularity   30 (9)    27 (11)   
   Lymphocyte rich      2 (<1)  12 (5)   
   Lymphocyte depletion             1 (<1)   0 (0)   
   Unclassified           21 (6)   39 (16)   
EBV status of tumorb      
   EBV positive   40 (22)   23 (22)   
   EBV negative 140 (78)  81 (78)   
Ann Arbor Stage      
   I-II 247 (72)   122 (51)  <0.0001 
   III-IV   95 (28)  113 (47)   
B symptoms        154 (45)    92 (38)  0.12 
Hemoglobin level<10.5g/dl   44 (13)    32 (13)  0.77 
ESR≥50        146 (43)    50 (21)  0.03 
White-cell count≥15,000/mm3   71 (21)    30 (13)  0.01 
Lymphocyte count<600/mm3          25 (7)    29 (12)  0.02 
Albumin level<40g/l        145 (42)  103 (43)  0.32 
IPS      
   0-2 229 (73)   120 (50)  <0.0001 
   3-7   84 (27)   119 (50)   
Treatment      
   ABVD 206 (60)   214 (90)  <0.0001d 
   EBVP  76 (22)  -   
   BEACOPP  41 (12)  -   
   Other regimens 19 (6)    10 (4)   
   Stanford V -    12 (5)   
   MOPP -     3 (1)   
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Table S1. Clinical, biologic characteristics and treatment of classical Hodgkin lymphoma 
patients 
  LYSA  SPORE   
 N=342 (%)  N=239 (%)  P-value 
Abbreviations: EBV, Epstein - Barr virus; ECOG, Eastern Cooperative Oncology Group; 
PS, performance status; ESR, erythrocyte sedimentation rate; IPS, international prognostic 
score; ABVD, doxorubicin, bleomycin, vinblastine, dacarbazine; EBVP, epirubicin, 
bleomycin, cyclophosphamide, vincristine, prednisone; BEACOPP, bleomycin, etoposide, 
doxorubin, cyclophosphamide, vincristin, procarbazine, prednisone; MOPP, caryolysine, 
vincristine, vinblastine, procarbazine. 
aIn accordance with French law, race or ethnicity could not be collected. This cohort 
likely reflects the genetic heterogeneity of the French population, which is dominated by 
Western-European ancestry given the national scope of this prospective study. 
bEBV status was obtained in 180 (53%) and 104 (48%) patients in LYSA and SPORE 
cohorts, respectively. In the LYSA, EBV status was obtained by immunohistochemical 
detection of latent membrane protein-1 (LMP-1) in 134 patients (75%), by EBER in situ 
hybridization in 37 patients (21%) or by other techniques in the remaining 7 patients 
(4%). In the SPORE EBV status was performed by EBER in situ hybridization. 
cP-value compared nodular-sclerosis versus other.  
dP-value compared ABVD versus other. 
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Table S2. Genotyping of the seven SNPs in the two cohorts 
   LYSA  SPORE  GWASa 
  n=342  n=239  Cases Controls 
  N (%) MAF  N (%) MAF  MAF 
2p16 (REL) AA 104 (30) 0.44    75 (31) 0.46  0.48 0.40 
rs1432295 AG 173 (51)   110 (46)       
 GG  65 (19)     54 (23)       
6p21 (HLA-DRA) AA   95 (28) 0.50    85 (36) 0.42  0.40 0.27 
rs6903608 AG 155 (45)   108 (45)       
 GG  92 (27)       46 (19)       
8q24 (MYC/PVT1) GG 112 (33) 0.43    64 (27) 0.46  0.41 0.48 
rs2608053 GA 168 (49)   128 (54)       
 AA   62 (18)     47 (20)       
8q24 (MYC/PVT1) AA   176 (51) 0.29  125 (52) 0.29  0.29 0.23 
rs2019960 AG  135 (40)     91 (38)       
 GG  31 (9)     23 (10)       
10p14 (GATA3) AA 206 (60) 0.22  137 (57) 0.24  0.25 0.19 
rs501764 AG  121 (36)     87 (36)       
 GG 14 (4)     15 (6)       
10p14 (GATA3) GG  181 (53) 0.28  113 (47) 0.31  0.31 0.25 
rs485411 GA  133 (39)   106 (44)       
 AA  28 (8)   20 (8)     
19p13.3 (TCF3) AA 107 (35) 0.42  79 (39) 0.39  0.35b 0.41b 
rs1860661 AG 140 (46)   87 (43)     
 GG   56 (18)   35 (17)       
Abbreviations: MAF, minor allele frequency; GWAS, genome wide-association 
study. 
aData for the GWAS from Enciso-Mora et al (2010), except for TCF3. 
bData from the discovery phase of the meta-analysis GWAS from Cozen et al 
(2014).  Of note, our cases were analyzed as part of the validation phase of this 
study. 
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Table S3. P-value (Chi-square test) evaluating the correlation between clinical characteristics and the genotyping of the seven studied 
SNPs in the LYSA cohort 
 
REL 
rs1432295 
HLA-DRA 
rs6903608 
MYC/PVT1 
rs2608053 
MYC/PVT1 
rs2019960 
GATA3 
rs501764 
GATA3 
rs485411 
 
TCF3 
rs1860661 
Age ≥45 years 0.09 0.23 0.80 0.25 0.25 0.50 0.91 
Male 0.74 0.43 0.75 0.69 0.76 0.85 0.29 
Stage III/IV 1.00 0.79 0.23 0.27 0.86 0.94 0.91 
Nodular sclerosis vs other 0.73 0.25 0.98 0.17 0.21 0.14 0.49 
ECOG PS 0.58 0.89 0.001a 0.48 0.77 0.66 0.09 
B Symptoms 0.53 0.06 0.93 0.32 0.41 0.26 0.41 
Hemoglobin level<10.5g/dl 0.81 0.53 0.24 0.85 0.69 0.58 0.29 
White-cell count≥15,000/mm3 0.52 0.12 0.23 0.95 0.69 0.52 0.29 
ESR<50 0.18 0.15 0.49 0.66 0.85 0.78 0.50 
Lymphocyte Count<600/mm3 0.68 0.47 0.14 0.99 0.21 0.42 0.82 
Albumin<40g/l 0.26 0.20 0.55 0.72 0.90 0.94 0.33 
IPS 0.52 0.64 0.59 0.20 0.44 0.60 0.95 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; ESR, erythrocyte sedimentation rate; IPS, 
international prognostic score. 
aPS 0-2: GG: 94 (84%), AG: 150 (89%), GG: 51 (82%) 
 PS 2-4: GG: 1 (1%), AG: 2 (1%), GG: 6 (10%) 
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Table S4. P-value (Chi-square test) evaluating  the correlation between clinical characteristics and the genotyping of the seven studied 
SNPs in the SPORE cohort 
 
REL 
rs1432295 
HLA-DRA 
rs6903608 
MYC/PVT1 
rs2608053 
MYC/PVT1 
rs2019960 
GATA3 
rs501764 
GATA3 
rs485411 
TCF3 
rs1860661 
Age ≥45 years 0.05 0.03a 0.23 0.21 0.61 0.31 0.12 
Male 0.43 0.32 0.41 0.83 0.73 0.46 0.47 
Ann Arbor stage III/IV 0.59 0.62 0.55 0.62 0.95 0.36 0.02
b 
Nodular sclerosis vs. other 0.66 0.20 0.49 0.89 0.38 0.05c 0.09 
ECOG PS 0.55 0.77 0.56 0.55 0.22 0.84 0.65 
B Symptoms 0.86 0.002d 0.61 0.43 0.81 0.92 0.16 
Hemoglobin level <10.5g/dl 0.29 0.09 0.29 0.88 0.22 0.13 0.06 
White-cell count≥15,000/mm3 0.63 0.79 0.88 0.55 0.44 0.88 0.67 
ESR < 50 0.46 0.73 0.30 0.63 0.31 0.48 0.69 
Lymphocyte Count<600/mm3 0.79 0.69 0.04e 0.76 0.33 0.22 0.45 
Albumin<40g/l 0.63 0.87 0.28 0.77 0.92 0.41 0.90 
IPS 0.99 0.30 0.22 0.87 0.19 0.23 0.38 
Abbreviations: ECOG, Eastern Cooperative Oncology Group; PS, performance status; ESR, erythrocyte sedimentation rate; IPS, 
international prognostic score. 
a Age <45: GG (n=50, 59%), AG (n=61, 56%), AA (n=36, 78%) 
  Age ≥45:  GG (n=35, 41%), AG (n=47, 44%), AA (n=19, 22%) 
b Stage I-II: AA (n=44, 57%), AG (n=49, 56%), GG (n=10, 29%) 
  Stage III-IV: AA (n=35, 43%), AG (n=36, 41%), GG (n=24, 69%) 
c Nodular sclerosis: AA (n=82, 73%), AG (n=70, 66%), GG (n=9, 45%) 
  Other: AA (n=31, 27%), AG (n=36, 34%), GG (n=11, 55%) 
d B symptoms: GG (n=43, 51%), AG (n=40, 27%), AA (n=9, 20%) 
  No B symptoms:  GG (n=42, 49%), AG (n=68, 63%), AA (n=37, 80%) 
e Lymphocyte Count<600/mm3: GG (n=4, 6%), AG (n=15, 12%), AA (n=10, 21%) 
  Lymphocyte Count≥600/mm3:  GG (n=55, 86%), AG (n=103, 80%), AA (n=31, 66%) 
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Table S5. Univariate analysis of MYC/PVT1 rs2608053 (dominant model) with progression-free survival by classical Hodgkin lymphoma 
subgroup in LYSA and SPORE cohorts 
 
 
LYSA  SPORE 
Subgroup N Events HR (95%CI) P  N Events HR (95%CI) P 
All patients 342 58 1.76 (0.95-3.26) 0.07  238 57 2.22 (1.09-4.54) 0.03 
Nodular Sclerosis 288 49 2.02 (1.01-4.05) 0.05  161 35 2.65 (1.03-6.85) 0.04 
Other cHL subtypes   54   9 0.89 (0.22-3.58) 0.87    77 22 1.38 (0.46-4.12) 0.56 
<45 years old 271 37 1.40 (0.68-2.90) 0.36  147 27 2.20 (0.76-6.38) 0.15 
≥45 years old   71 21 2.75 (0.81-9.35) 0.10    91 30 2.23 (0.85-5.85) 0.10 
Males 196 38 2.73 (1.14-6.53) 0.02  124 35 1.42 (0.52-3.85) 0.02 
Females 146 20 0.93 (0.37-2.33) 0.88  114 22 6.47 (0.86-49.0) 0.49 
Ann Arbor Stage I-II 247 33 2.15 (0.93-4.96) 0.07  122 18 2.05 (0.90-4.66) 0.07 
Ann Arbor Stage III-IV   95 25 1.08 (0.43-2.72) 0.86  112 38 2.22 (1.09-4.54) 0.09 
Abbreviations: HR, hazard ratio; CI, confidence interval, cHL, classical Hodgkin lymphoma; EBV, Epstein-Barr Virus. 
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Table S6. Univariate associations of SNPs (dominant model) with progression-free survival in classical Hodgkin lymphoma stratified by EBV tumor status. 
 EBV- cHL  EBV+ cHL 
 LYSA  SPORE  LYSA  SPORE 
Gene and SNP N, Events HR (95%CI) P  N, Events HR (95%CI) P  N, Events HR (95%CI) P  N, Events HR (95%CI) P 
REL, rs1432295 140 26 0.93 (0.40-2.14) 0.86   81 16 2.38 (0.54-10.5) 0.25  40 8 0.44 (0.11-1.77) 0.25   23 11 3.47 (0.89-13.6) 0.07 
HLA-DRA, rs6903608 140 26 0.67 (0.30-1.51) 0.33   81 16 0.35 (0.13-0.94) 0.04  40 8 0.91 (0.22-3.80) 0.90   23 11 1.62 (0.46-5.74) 0.46 
MYC/PVT1, rs2608053 140 26 1.72 (0.65-4.55) 0.28   81 16 2.38 (0.67-8.40) 0.18  40 8 1.40 (0.28-6.93) 0.68   23 11 0.96 (0.20-4.66) 0.96 
MYC/PVT1, rs2019960 140 26 1.01 (0.47-2.18) 0.98  81 16 0.72 (0.27-1.92) 0.51  40 8 0.90 (0.22-3.77) 0.89  23 11 0.64 (0.16-2.48) 0.52 
GATA3, rs501764 140 26 1.58 (0.73-3.42) 0.24  81 16 0.69 (0.25-1.89) 0.47  40 8 2.17 (0.54-8.67) 0.27  23 11 0.92 (0.23-3.69) 0.91 
GATA3, rs485411 140 26 1.41 (0.65-3.07) 0.38  81 16 0.98 (0.36-2.62) 0.96  40 8 1.67 (0.42-6.70) 0.47  23 11 1.62 (0.43-6.05) 0.47 
TCF3, rs1860661 121 21 1.48 (0.60-3.67) 0.40  72 16 0.91 (0.34-2.45) 0.85  35 6 0.42 (0.08-2.10) 0.29  19   8 0.77 (0.14-4.24) 0.77 
Abbreviations: cHL, classical Hodgkin lymphoma; EBV, Epstein-Barr Virus; HR, hazard ratio; CI, confidence interval.  
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Table S7. Single nucleotide polymorphisms in linkage disequilibrium with MYC/PVT1 rs2608053 on 
chromosome 8 according to 1000 Genomes Projecta  
SNPa Positionb r2 
rs2720665 129076509 0.87 
rs2608052 129076284 0.72 
rs1499363 129074902 0.66 
rs2720658 129059423 0.65 
rs2648861 129059568 0.65 
rs12547679 129053040 0.64 
rs11775301 129059110 0.61 
rs2648879 129073712 0.58 
rs58467928 129074450 0.55 
rs2720660 129061242 0.52 
rs2648876 129072966 0.52 
rs13250078 129070428 0.52 
rs13248311 129070559 0.52 
rs35916594 129069820 0.51 
aAbecacis et al, 2012 
bThe research of the SNPs was performed from 112076290 and 146075832 position that convers PVT1 and MYC 
loci 
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Fig S1. MYC/PVT1 rs2608053 is located in epigenetic regulatory domain with high PhastCons and 
PolyP conservation scores across Mammal and Vertebrates according to UCSC GoldenPath 
Database 
 
We investigated the potential functional roles of rs2608053 and the 14 SNPs in LD with rs2608053 
(Table S7) using data from the Encode Projecta and UCSC GoldenPath Databaseb. Since neither 
rs2608053 nor other SNPs in LD with rs2608053 are located in exons, we hypothesized that 
rs2608053 is a regulatory SNP or is in LD with a regulatory SNP. Among the 15 SNPs investigated 
including rs2608053, only rs2720660 is located in an evolutionarily conserved region. As shown 
in the Figure above, rs2720660 (r2 = 0.52) is in elements conserved across both vertebrates and 
placental mammals, as calculated using two methods (phastCons and pyloP) from the PHAST 
packagec. Further evidence of rs2720660 as a regulatory SNP comes from the ENCODE epi-
genetic marker profiling data of cell lines. The figure above only displays the data from GM12878, 
a lymphoblastoid cell line. Specifically, rs2720660 was found in the H3K4Me1 mark which is 
often found near regulatory elements, as well as the H3K27Ac mark which is usually near “active” 
regulatory elements. 
aThe ENCODE (ENCyclopedia Of DNA Elements) Project. Science 2004; 306: 636-640. 
http://genome.ucsc.edu/ENCODE/ [Accessed April 09, 2013]. 
bUCSC GoldenPath database. http://genome.ucsc.edu/ [Accessed April 09, 2013].  
cPHAST package: http://compgen.bscb.cornell.edu/phast/ [Accessed April 09, 2013].
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Fig S2. MetaCore Regulatory Network Analyses of miR-1207-5p targets using the Auto-Expand 
algorithm 
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Fig S3. Expression of HBEGF in lymph nodes and other tissues based on Microarray (left panel), 
RNAseq (center panel), and Serial Analysis of Gene Expression (SAGE, right panel) data from 
GTEx, BioGPS, Illumina Human BodyMap, and SAGE. The image of the expression profile is 
compiled by GeneCards (http://www.genecards.org/) 
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